文献速递头颈与中枢神经肿瘤

抗凝药使用与新诊断胶质母细胞瘤结局的关联

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
PubMed 文献 · Eur J Cancer · 2018-07-20

该研究 pooled 三项新诊断胶质母细胞瘤随机临床试验共1273例患者数据,分析基线至替莫唑胺放化疗开始(Ⅰ期)及此后至维持替莫唑胺化疗开始(Ⅱ期)抗凝药使用与生存的关联。结果显示Ⅱ期抗凝药使用与更差的总生存相关(p=0.001,HR=1.52,95%CI 1.18-1.95),抗凝药未改善总生存,可能不具有相关抗肿瘤作用。

要点

  • Ⅱ期抗凝药使用与更差OS相关(HR=1.52,95%CI 1.18-1.95,p=0.001)。
  • 仅预防性抗凝患者中未见OS下降。
  • 抗血小板药使用未发现生存关联。

核心结论

  • 抗凝药使用与总生存改善无关。
  • 抗凝药可能在新诊断胶质母细胞瘤中不具有相关抗肿瘤特性。

研究设计与样本

  • 汇总三项新诊断胶质母细胞瘤随机临床试验数据,共1273例患者。
  • 评估基线至替莫唑胺放化疗开始(Ⅰ期)及此后至维持替莫唑胺化疗开始(Ⅱ期)的抗凝药使用与生存关联。
  • 采用Cox回归模型,按试验分层并校正基线预后因素。

主要发现

  • Ⅰ期抗凝药使用记录于75例患者(5.9%),Ⅱ期记录于104例患者(10.2%)。
  • 多因素分析中,Ⅱ期抗凝药使用较未使用与更差OS相关(p=0.001,HR=1.52,95%CI 1.18-1.95),Ⅰ期未见此关联。
  • 仅纳入预防性抗凝患者时未见OS下降。
  • 抗血小板药使用未建立生存关联。

临床怎么用

  • 胶质母细胞瘤患者使用抗凝药不应期望通过抗肿瘤作用改善生存。
  • 预防性抗凝未显示OS下降,但研究未支持抗凝药改善结局的假设。

局限性

  • 抗凝药使用为观察性记录,非随机分组,可能存在混杂。
  • 数据来自三项随机临床试验的汇总分析,抗凝药使用比例较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To test the hypothesis that despite bleeding risk, anticoagulants improve the outcome in glioblastoma because of reduced incidence of venous thromboembolic events and modulation of angiogenesis, infiltration and invasion. METHODS: We assessed survival associations of anticoagulant use from baseline up to the start of temozolomide chemoradiotherapy (TMZ/RT) (period I) and from there to the start of maintenance TMZ chemotherapy (period II) by pooling data of three randomised clinical trials in newly diagnosed glioblastoma including 1273 patients. Progression-free survival (PFS) and overall survival (OS) were compared between patients with anticoagulant use versus no use; therapeutic versus prophylactic versus no use; different durations of anticoagulant use versus no use; anticoagulant use versus use of anti-platelet agents versus neither anticoagulant nor anti-platelet agent use. Cox regression models were stratified by trial and adjusted for baseline prognostic factors. RESULTS: Anticoagulant use was documented in 75 patients (5.9%) in period I and in 104 patients (10.2%) in period II. Anticoagulant use during period II, but not period I, was associated with inferior OS than no use on multivariate analysis (p = 0.001, hazard ratio [HR] = 1.52, 95% confidence interval [CI]: 1.18-1.95). No decrease in OS became apparent when only patients with prophylactic anticoagulant use were considered. No survival association was established for anti-platelet agent use. CONCLUSIONS: Anticoagulant use was not associated with improved OS. Anticoagulants may not exert relevant anti-tumour properties in glioblastoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Genbrugge E, Stupp R, et al. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. Eur J Cancer. 2018. PMID: 30036741. doi:10.1016/j.ejca.2018.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。